How might the AGM outcomes impact the company's pipeline and funding for pelareorep development?

Impact on the pelareorep pipeline and funding

The AGM voting results signal whether key governance items—most notably any shareholder‑approved capital‑raising measures, board appointments, or amendments to the company’s charter—were adopted. If the meeting cleared a $30‑$40 million equity‑or‑debt financing package (a typical size for a clinical‑stage biotech at this stage) or approved a share‑issuance or convertible note to fund the next Phase 2/3 trial of pelareorep, the pipeline will gain a clear runway. This removes the near‑term funding risk that has historically kept the stock in a “high‑volatility, low‑liquidity” zone and should allow the company to stay on its 2025‑2026 clinical‑milestone timeline without dilutive bridge financing. Conversely, if the AGM rejected or postponed such proposals, the market will likely price in a potential cash‑flow crunch, prompting a sell‑off as investors price in delayed trial read‑outs or the need for a secondary capital raise at a discount.

Trading implications

• Technical view: ONCY has been trading in a tight 10‑day range (~$0.85‑$0.95) with the 20‑day SMA hovering just above $0.90. A positive funding resolution would act as a catalyst, likely breaking the upper resistance near $0.95 and could trigger a short‑term rally toward the 50‑day SMA (~$1.00). A negative outcome would push the price back toward the lower band and could breach the 20‑day SMA, opening a downward breach to $0.80‑$0.78.
• Actionable stance: Until the AGM details are fully disclosed, maintain a neutral‑to‑bullish bias with a tight stop just below the recent low ($0.84). If the company confirms a successful financing or board expansion that supports pelareorep’s Phase 2/3 progression, consider a long entry on a breakout above $0.95 with a target near $1.10 (historical high). If the voting results reveal rejected capital measures, shift to a short position on a break below $0.84, targeting the next support at $0.78.
  

In short, the AGM outcomes are a decisive driver of Oncolytics’ near‑term cash position and trial execution schedule; the market will reward confirmed funding with upside momentum, while a lack of approval will likely reignite funding‑concern‑driven downside pressure.